Mega Genomics

Mega Genomics P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Mega Genomics (6667.HK) as of Oct 21, 2026 is -69.06. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was 20.43 — a change of -437.97% (lower).

P/FCF

-69.06

YoY

-437.97%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Mega Genomics is 2025 -69.06 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Mega Genomics was 2024 20.43 . It decreases by -437.97% lower compared to the previous year.

The Mega Genomics P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2019
36.80 CNY
Jan 1, 2020
13.20 CNY
Jan 1, 2021
43.95 CNY
Jan 1, 2022
-95.21 CNY
Jan 1, 2023
10.53 CNY
Jan 1, 2024
20.43 CNY
Jan 1, 2025
-69.06 CNY
The Mega Genomics P/FCF history
YEARP/FCFYoY
-69.06-437.97%
20.43+94.01%
10.53-111.06%
-95.21-316.60%
43.95+232.97%
13.20-64.13%
36.80—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Mega Genomics Stock analysis

What does Mega Genomics do? Mega Genomics Ltd. generates revenue through three business segments. The Consumer Genetic Testing Services segment offers nutrition and metabolism testing, cancer risk assessment, chronic disease susceptibility analysis, pharmacogenetic testing, and infectious disease testing to individual consumers. The Cancer Screening Services segment provides specific tests including Septin9 for colorectal cancer, Syndecan-2 (SDC2) for colorectal cancer, and ring finger protein 180 (RNF180)/Septin9 for gastric cancer screening. The Other Services segment delivers genetic research and analysis services to third-party research institutions, creating additional revenue streams from institutional partnerships. The primary buyers for Consumer Genetic Testing Services are individual consumers seeking personalized health insights. Cancer Screening Services are utilized by healthcare providers and patients for early detection of colorectal and gastric cancers. Third-party research institutions purchase genetic research and analysis services from the Other Services segment to support their scientific studies and development projects. Mega Genomics Ltd. serves distinct market segments: individual consumers for genetic testing, healthcare providers for cancer screening, and research institutions for specialized genetic analysis. The company's revenue model relies on direct consumer sales, healthcare provider contracts, and institutional research partnerships to sustain its operations and growth. Mega Genomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mega Genomics stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Mega Genomics is -69.06 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Mega Genomics changed from 20.43 to -69.06, representing a -437.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Mega Genomics since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Mega Genomics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Mega Genomics

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Mega Genomics